Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial
| Autor: | Brendan P. Halloran, Daniel C. Baumgart, Karen I. Kroeker, Bhairavi Balram, Levinus A. Dieleman, Harshad Joshi, Farhad Peerani, Karen Wong |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Physiology business.industry medicine.medical_treatment Gastroenterology Odds ratio Hepatology medicine.disease Ulcerative colitis Infliximab Aminosalicylate Discontinuation 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Concomitant Internal medicine medicine 030211 gastroenterology & hepatology business Colectomy medicine.drug |
| Zdroj: | Digestive Diseases and Sciences. 66:3985-3992 |
| ISSN: | 1573-2568 0163-2116 |
| Popis: | While there is recent literature to support the discontinuation of 5-aminosalicylate (5-ASA) upon the initiation of biologics, continuing 5-ASA after treatment failure is relatively common. We aimed to assess the impact of concomitant 5-ASA therapy on clinical outcomes in ulcerative colitis (UC) patients escalated to infliximab. This is a retrospective chart review of patients with moderate-to-severe UC started on infliximab between January 2012 and December 2017 at the University of Alberta. The primary outcome was clinical remission (partial Mayo score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink